Drug Trial Radar · NCT05074810
Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients
Last checked: Nov 19, 2026Latest source record: Jan 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
153
Planned (sponsor's estimate)
Start
Apr 12, 2022
Primary completion
Jun 2026
Study completion Apr 2027
Sponsor
- Lead sponsor
- Verastem, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Amgen
- First posted
- Oct 12, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study will assess the safety and efficacy of avutometinib (VS-6766) in combination with sotorasib with or without defactinib in patients with KRAS G12C Non-Small Cell Lung Cancer (NSCLC) in patients who have been exposed to prior G12C inhibitor and those who have not been exposed to prior G12C inhibitor.
Conditions
- Non Small Cell Lung Cancer
- KRAS Activating Mutation
Interventions
avutometinib and sotorasibDrug
The RP2D of avutometinib + sotorasib determined in Part A will be used in Part B dose expansion
avutometinib and sotorasib and defactinibDrug
The RP2D of avutometinib + sotorasib + defactinib determined in Part A will be used in Part B dose expansion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: To determine RP2D for avutometinib in combination with sotorasib and the Alt-RP2D for avutometinib in combination with sotorasib and defactinibTime frame: From start of treatment to confirmation of RP2D; 28 days
- Part B: To determine the efficacy of the RP2D and/or Alt-RP2D identified from Part ATime frame: From start of treatment to confirmation of response; 16 weeks
Locations
35 sites in 6 countries. Site status is shown where the registry gives one.
Rocky Mountain Cancer Center, LLP
Boulder, Colorado
Georgetown University Medical Center
Washington D.C., District of Columbia
MedStar Washington Hospital Center, MedStar Georgetown Cancer Institute,
Washington D.C., District of Columbia
Illinois Cancer Specialists
Arlington Heights, Illinois
Maryland Oncology & Hematology, P.A.
Rockville, Maryland
Dana Farber Cancer Institute
Boston, Massachusetts
Henry Ford Health System
Detroit, Michigan
Minnesota Oncology Hematology, P.A
Woodbury, Minnesota
Washington University School of Medicine
St Louis, Missouri
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio
Ohio State University Brain and Spine Hospital
Columbus, Ohio
Consultants in Medical Oncology & Hematology
Broomall, Pennsylvania
Alliance Cancer Specialists,
Horsham, Pennsylvania
Texas Oncology
Austin, Texas
University of Texas Southwestern Medical Center
Dallas, Texas
Texas Oncology - Fort Worth Cancer Center
Fort Worth, Texas
Texas Oncology
Longview, Texas
Oncology and Hematology Associates of Southwest Virginia, Inc., DBA Blue Ridge Cancer Care
Blacksburg, Virginia
Virginia Cancer Specialists, PC
Fairfax, Virginia
Northwest Cancer Specialists
Vancouver, Washington
University Hospital Gent
Ghent, Belgium
CHU de Liège
Liège, Belgium
CHRU of Lille
Lille, France
Hôpital Cochin
Paris, France
Hôpital Foch
Suresnes, France
Leids Universitair Medisch Centrum
Leiden, Netherlands
Erasmus MC
Rotterdam, Netherlands
Hospital Teresa Herrera (C.H.U.A.C)
A Coruña, Spain
Hospital General Universitario Gregorio Marañón
Madrid, Spain
Hospital Universitario Fundación Jiménez Díaz
Madrid, Spain
Hospital Universitario Virgen De La Victoria
Málaga, Spain
Hospital Universitario Virgen de la Macarena
Seville, Spain
University of Leicester
Leicester, United Kingdom
Royal Marsden Hospital
London, United Kingdom
Royal Marsden Hospital
Sutton, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.